Abstract

An electrochemical method of recycling and regenerating transition metal oxides includes heating a mixture of salts to obtain a molten salt solution, and immersing a working electrode, a counter electrode and optionally a reference electrode into the molten salt solution, where the working electrode is electrically connected to a cathode material comprising a transition metal oxide. A voltage is applied to the working electrode, such that electrodissolution of the transition metal oxide occurs and an alkali metal species comprising lithium or sodium ions and a transition metal species comprising transition metal ions are produced in the molten salt solution. During application of the voltage and dissolution of the transition metal oxide, a regenerated transition metal oxide is concurrently electrochemically produced, e.g., in the form of a film or a powder.

IPC Classes  ?

• C01D 15/02 - Oxides; Hydroxides
• C25B 3/25 - Reduction
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

Disclosed are deuterated derivatives of tropolone useful for the treatment of diseases or disorders, e.g., involving deficiencies in iron transport.

Abstract

Disclosed is a method of treating a disease or condition characterized by neurodegeneration via administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of hinokitiol, hinokitiol derivatives, and iron-transporting tropolones.

Abstract

A device includes a porous scaffold characterized by a scaffold refractive index. An optically written optic is embedded in the porous scaffold. A coating forms a surface of the porous scaffold. The coating includes the surface and a transition region. The surface is characterized by a surface refractive index. The transition region is characterized by a refractive index gradient that transitions between the surface refractive index and the scaffold refractive index

IPC Classes  ?

• G02B 1/10 - Optical coatings produced by application to, or surface treatment of, optical elements
• G02B 6/02 - Optical fibres with cladding

Abstract

Aspects provide an intelligent direct input/output (IDIO) architecture for facilitating movement of data between processor cores and memories. A data packet is received at a network interface and classified based on its association with an application being processed by one or more cores of a processor. The disclosed IDIO architecture may determine to steer the data packet to a cache memory (e.g., a last level cache (LLC) or middle level cache (MLC)) or random access memory in response to receiving the data packet. The determination to steer the data packet to a particular memory may be based on characteristics of the data packet, the application, or other metrics. Where the data packet is steered to the MLC, the data packet may first be steered to the LLC and then prefetched to the MLC. The application may provide control information to invalidate a cacheline associated with the data packet one used.

IPC Classes  ?

• H04L 67/568 - Storing data temporarily at an intermediate stage, e.g. caching
• G06F 11/30 - Monitoring
• G06F 12/00 - Accessing, addressing or allocating within memory systems or architectures

Abstract

The disclosure provides an example Full Duplex-based ISAC optimization system. The system includes: (a) a Full Duplex (FD) massive MIMO Base Station (BS) node configured to operate at mmWave frequencies and having a plurality of transmitter antenna elements and a plurality of receiver antenna elements configured to communicate in a DownLink (DL) direction with a plurality of mobile users that each have a plurality of antenna receiver elements, where the plurality of RX antenna elements of the FD massive MIMO BS node are configured to receive DL signals reflected by a plurality of radar targets, and (b) at least one processor detects the plurality of radar targets randomly distributed within a communication environment based on the reflected DL signals, where the processor determines an estimation of a Direction of Arrival (DoA), a range, and a relative velocity for radar targets while optimizing a DL communication rate to the mobile users.

IPC Classes  ?

• H04B 7/0452 - Multi-user MIMO systems
• G01S 3/00 - Direction-finders for determining the direction from which infrasonic, sonic, ultrasonic, or electromagnetic waves, or particle emission, not having a directional significance, are being received
• G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
• H04B 7/0456 - Selection of precoding matrices or codebooks, e.g. using matrices for antenna weighting

Abstract

The current disclosure provides an improved sensitivity assay for detecting and quantifying nucleic acids in a sample. The assay utilizes target recycling amplification process (TRAP) for the digital detection of nucleic acids in tandem with photonic resonator absorption microscopy (PRAM) and utilizes toehold-mediated DNA strand displacement reactions. The disclosure also provides a system and method for use of the assay.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Herein is described the development of NIR-nanogels for NIR light-mediated cargo delivery. NIR-nanogels feature a photolabile cyanine crosslinker that can cleave via dioxetane chemistry when irradiated. This photochemical process results in the formation of two carbonyl fragments and concomitant NIR-nanogel degradation to facilitate cargo release. In contrast to studies where cyanines are utilized as photocages, our approach does not require direct chemical attachment to the cargo, thus expanding our ability to deliver molecules that cannot be covalently modified. We showcase this feature by encapsulating a palette of small-molecule chemotherapeutics that feature structurally diverse chemical architecture.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61K 49/04 - X-ray contrast preparations
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The attachment of glucose to drugs and imaging agents enables cancer cell targeting via interactions with GLUT1 overexpressed on the cell surface. The present technology describes a biomimetic approach for the design of a multivalent glucose moiety (mvGlu). We showcase the utility of this new group by developing aza-BODIPY-based contrast agents boasting a significant PA signal enhancement greater than 11-fold after spectral unmixing. Moreover, when applied to targeting cancer cells, effective staining could be achieved with ultra-low dye concentrations (50 nM) and compared to a non-targeted analog, the signal intensity was >1000-fold higher. Also, we employed the mvGlu technology to develop a logic-gated acoustogenic probe to detect intratumoral Cu(I), which is an emerging cancer biomarker, in a murine model of breast tumor. This application was not possible using other acoustogenic probes previously developed for copper sensing.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/69 - Boron compounds
• A61K 31/4192 - 1,2,3-Triazoles

Abstract

Disclosed are prodrugs of MYC inhibitors and methods making and using same.

IPC Classes  ?

• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61K 31/415 - 1,2-Diazoles
• A61P 35/00 - Antineoplastic agents

Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for the survival of parasitic worms. In one aspect, the compounds described herein treat diseases produced by parasitic worms such as, for example, praziquantel-resistant worms.

IPC Classes  ?

• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/38 - Nitrogen atoms
• C07D 235/12 - Radicals substituted by oxygen atoms
• C07D 235/14 - Radicals substituted by nitrogen atoms
• C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 235/24 - Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 263/56 - Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• C07D 271/06 - 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
• C07D 271/10 - 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• A61P 33/12 - Schistosomicides
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/4245 - Oxadiazoles
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/42 - Oxazoles

Abstract

A methodology is used to quantify implications and/or footprints of carbon, water, and/or nutrients of a particular crop in a region on a large scale and at field-level. A methodology is used to quantify, calculate, and/or visualize cover crop traits, tillage practices, and/or their outcomes at large scale. A methodology is used to accurately derive, estimate, and/or predict large-scale, long-term, and field-level cover crop adoption and biomass information using remote sensing time series.

IPC Classes  ?

• G06Q 10/0637 - Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
• G06Q 50/02 - Agriculture; Fishing; Mining

Abstract

Disclosed are isolated nanoparticles composed of an extracellular matrix which comprises at least one heparin binding domain and nucleic acid or polyphosphate, as well as compositions comprising the nanoparticles and methods of treating tissue Injury.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds can also label the Aβ species in the brain sections of transgenic AD mice, as shown by immunostaining with an Aβ antibody. Certain amphiphilic compounds were found to alleviate the Cu2+-Aβ induced toxicity in cell viability assays. Additionally, two compounds, ZY-15-MT and ZY-15-OMe, were found to disrupt the interactions between Aβ oligomers and human neuroblastoma SH-SY5Y cell membranes. These studies show compounds with amphiphilic properties that target Aβ oligomers and modulate the Aβ oligomer-cell membrane interactions can be effective as small molecule AD therapeutics. Also, the disclosed amphiphilic dicyanomethylene compounds that can emit in the near-infrared region and chelate copper can be used as early diagnostic agents for AD.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 49/00 - Preparations for testing in vivo
• A61K 51/04 - Organic compounds
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The disclosure provides an example charging nest for wireless power transfer to drones is disclosed. The charging nest includes (a) a housing having an opening at a first end, (b) a plurality of antennas arranged around a periphery of the housing with each antenna aperture arranged facing a center of the housing, where each of the plurality of antennas has a director, an exciter, and a plurality of reflectors, and (c) a plurality of transmitters or transceivers each electrically coupled to a corresponding exciter of the plurality of antennas.

IPC Classes  ?

• B60L 53/30 - Constructional details of charging stations
• B60L 53/12 - Inductive energy transfer
• H02J 50/20 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves
• H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
• B64C 39/02 - Aircraft not otherwise provided for characterised by special use

Abstract

Disclosed are polypeptides and methods of glycosylating the C19 hydroxyl group of AmdeB (i.e., amphotericin B lacking the sugar moiety) comprising contacting AmdeB with a saccharide in the presence of one of the polypeptides. The methods access compounds that are analogues of amphotericin B with a modified sugar moiety that have an improved therapeutic index, such as C2'epiAmB. Also disclosed are pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• C12P 19/62 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin

Abstract

P. aeruginosa E. coliP. aeruginosa E. coliP. aeruginosaP. aeruginosaP. aeruginosaP. aeruginosa P. aeruginosa including dozens of clinical isolates.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Abstract

A non-contact clinical Raman spectroscopy guided probe includes at least one first fiber operably coupled with a first light source and having a working end for delivering excitation light emitted from the first light source to the target site; at least one second fiber operably coupled with a detector and having a working end for collecting Raman scattering light scattered from the target site in response to excitation by the excitation light to the detector; and a lens positioned between the working ends of the at least one first fiber and the at least one second fiber and the target site for focusing the excitation light onto the target site and retrieving collection efficiency of the Raman scattering light. The probe is also guided during device positioning to provide the user with feedback on orientation in the lateral and axial directions to repeatably measure specific locations on the target site.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
• G01J 3/44 - Raman spectrometry; Scattering spectrometry
• G01J 3/02 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours - Details

Abstract

Disclosed are compositions comprising a lipid polymer excipient and AmB or an AmB derivative. The lipid polymer excipient can form micelles when formulated with AmB or the AmB derivative and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection comprising administering to a subject in need thereof a therapeutically effective amount of a composition.

IPC Classes  ?

• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• A61P 31/10 - Antimycotics

Abstract

This disclosure relates to processes for converting saturated polyethylene to at least an alkene product. The processes comprise contacting the saturated polyethylene with three or more catalyst components in a reactor, the reactor comprising an alkene reactant. The three or more catalyst components comprise a metathesis catalyst component, an isomerization catalyst component, and a dehydrogenation catalyst component. Contacting causes at least a portion of the saturated polyethylene to undergo dehydrogenation reactions to form unsaturated polyethylene and at least a portion of the unsaturated polyethylene, or products derived therefrom, to undergo metathesis reactions and isomerization reactions to produce an effluent comprising at least the alkene product.

IPC Classes  ?

• C07C 6/04 - Metathesis reactions at an unsaturated carbon-to-carbon bond at a carbon-to-carbon double bond
• C07C 11/06 - Propene
• C07C 11/04 - Ethene
• C07C 11/02 - Alkenes
• C07C 4/08 - Preparation of hydrocarbons from hydrocarbons containing a larger number of carbon atoms by splitting-off an aliphatic or cycloaliphatic part from the molecule
• C07C 5/373 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen with simultaneous isomerisation
• B01J 21/12 - Silica and alumina
• C07C 6/00 - Preparation of hydrocarbons from hydrocarbons containing a different number of carbon atoms by redistribution reactions

Abstract

This disclosure relates to processes for converting unsaturated polyethylene to at least an alkene product. The processes comprise contacting the unsaturated polyethylene with two or more catalyst components in a reactor comprising an alkene reactant. The two or more catalyst components comprise a metathesis catalyst component and an isomerization catalyst component. Contacting causes at least a portion of the unsaturated polyethylene, or products derived therefrom, to undergo metathesis reactions and isomerization reactions to produce an effluent comprising at least the alkene product.

IPC Classes  ?

• C07C 6/04 - Metathesis reactions at an unsaturated carbon-to-carbon bond at a carbon-to-carbon double bond
• C07C 11/06 - Propene
• C07C 11/04 - Ethene
• C07C 11/02 - Alkenes
• C07C 4/08 - Preparation of hydrocarbons from hydrocarbons containing a larger number of carbon atoms by splitting-off an aliphatic or cycloaliphatic part from the molecule
• B01J 32/00 - Catalyst carriers in general
• B01J 21/04 - Alumina
• B01J 27/10 - Chlorides
• B01J 31/12 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing organo-metallic compounds or metal hydrides

Abstract

Provided herein are compositions and methods for producing pyridine-based macrocyclic peptides.

IPC Classes  ?

• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C12N 9/50 - Proteinases
• C12N 9/88 - Lyases (4.)
• C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

A system for selective electrodeposition for metal recycling includes an electrochemical cell comprising: a fluid including first and second transition metals and a salt at a molar concentration of greater than 1 M; a working electrode in contact with the fluid, where the working electrode has a surface coated with a positively charged polyelectrolyte; and a counter electrode in contact with the fluid and spaced apart from the working electrode. The system also includes a power supply electrically connected to the working and counter electrodes.

IPC Classes  ?

• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes
• C22B 3/04 - Extraction of metal compounds from ores or concentrates by wet processes by leaching
• C22B 7/006 -
• C25B 9/65 - Means for supplying current; Electrode connections; Electric inter-cell connections
• C25C 1/08 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of iron group metals, refractory metals or manganese of nickel or cobalt
• C25C 7/02 - Electrodes; Connections thereof
• C25D 17/10 - Electrodes
• C22B 3/10 - Hydrochloric acid
• H01M 10/052 - Li-accumulators
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• H01M 4/52 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron

Abstract

The disclosure provides for methods of detecting target polynucleotides in a biological sample from a subject including the steps of extracting the target polynucleotides from the biological sample and subjecting the biological sample to conditions that amplify the target polynucleotides in the biological sample using a polymerase chain reaction (PCR) and detecting the target polynucleotides in biological sample. The methods may be used to detect Human Papilloma Virus (HPV) mediated squamous cell carcinoma or non-HPV mediated squamous cell carcinoma.

IPC Classes  ?

• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

Provided are fluorescent nanoparticle and related methods of using the fluorescent nanoparticles for imaging tumors. The fluorescent nanoparticle comprises a gelatin matrix; and a fluorophore encapsulated within the gelatin matrix and ionically-bound to the gelatin matrix. The encapsulated fluorophore has an encapsulation concentration selected to provide: quenching of fluorophore encapsulated within the gelatin matrix and a substantial fluorescence for the fluorophore released from the gelatin matrix.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

Thermoset resin compositions including a compound of formula (I) having a working life and/or a pot life of at least 1 hour are provided. Copolymers prepared from the thermoset resin compositions are further provided. Methods of preparing and polymerizing the thermoset resin compositions are further provided. Delivery devices for preparing thermoset resin compositions are further provided.

IPC Classes  ?

• C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
• C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers

Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds (I) that are inhibitors for spleen tyrosine kinase (Syk), which is a key signaling protein in hematologic cells and implicated in multiple hematopoietic malignancies, cancer (e.g., chronic lymphoid leukemia (CLL) or acute myeloid leukemia (AML) ), diabetes, and immune disorders. In one aspect, the compounds described herein drug resistance, which renders current ATP- competitive Syk inhibitors ineffective.

IPC Classes  ?

• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 239/42 - One nitrogen atom
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

The present invention provides use of amphiphilic amine-terminated poly(amidoamine) (PAMAM) dendrimers and bola-amphiphilic amine-terminated PAMAM dendrimer and particles formed by said dendrimers as antipathogenic agents. Specifically, antibacterial use of compositions comprising these dendrimers is presented. Provided also particles formed by said dendrimers encapsulating antibacterial agents and use of such loaded particles for treatments of pathogenic infections such as bacterial infections.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61P 31/04 - Antibacterial agents
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 31/65 - Tetracyclines
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 38/14 - Peptides containing saccharide radicals; Derivatives thereof
• A61K 9/51 - Nanocapsules
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• C08G 73/02 - Polyamines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/785 - Polymers containing nitrogen
• A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Methods of preparing oligomers including heating a mixture of an amount of a functionalized cycloalkene, an amount of a chain transfer agent, a phosphite ester, and a catalyst, a degree of polymerization of the oligomers controllable by a molar ratio of the amount of the functionalized cycloalkene to the amount of the chain transfer agent, are provided herein. Methods of preparing polymers including heating the oligomers and a second amount of the functionalized cycloalkene, a phosphite ester, and a catalyst are further provided. Compositions of oligomers and functionalized cycloalkenes are further provided.

IPC Classes  ?

• C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
• C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers
• C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Coating compositions based on derivatives of such polymers

Abstract

Methods for recycling oligomeric units derived from a first polymer into a second polymer are provided herein. Methods of preparing oligomeric macromonomers from oligomeric units are further provided. Methods of polymerizing oligomeric macromonomers are further provided.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08G 61/00 - Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule

Abstract

22222242425333622.

IPC Classes  ?

• C25B 15/00 - Operating or servicing cells
• C25B 11/047 - Ceramics
• C25B 11/046 - Alloys
• C25B 11/03 - Electrodes; Manufacture thereof not otherwise provided for characterised by shape or form perforated or foraminous
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
• C25B 3/26 - Reduction of carbon dioxide
• C25B 3/07 - Oxygen containing compounds
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 1/23 - Carbon monoxide or syngas
• B01D 53/86 - Catalytic processes
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• B01D 53/73 - After-treatment of removed components
• B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
• B01D 53/24 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by centrifugal force
• B01D 53/62 - Carbon oxides

Abstract

Provided herein are exosomes (such as modified exosomes) that include or express one or more surface proteins that are covalently linked to an immunomodulatory molecule or a therapeutic molecule. In particular examples, the exosomes are from a cancer cell, a stem cell, or an immune cell. Also provided are methods of making and using the modified exosomes, for example for treating cancer.

IPC Classes  ?

• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides an example method for using an MRI system electrically coupled to a computing device. The method includes generating, via the MRI system, an echo-shifted echo- planar imaging with blip up/down acquisition ("esEPI-BUDA") pulse sequence including a first radiofrequency ("RF") pulse and a second RF pulse, the first RF pulse followed by a first echo- train that is interleaved with the first and the second RF pulses, and the second RF pulse followed by a second echo-train such that the first and the second echo-trains have opposite phase-encoding blip gradient polarities to traverse echo planar imaging ("EPI") k-space in a reversed order. In response to the pulse sequence being generated, the MRI system acquires two k-space datasets within a single shot and corrects image distortion, via the MRI system, based on the two acquired k-space datasets.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/48 - NMR imaging systems
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux

Abstract

A time-efficient diffusion magnetic resonance imaging systems and methods are provided that can produce multiple diffusion-weighted images with different b-values in one repetition time, and/or multiple diffusion-weighted images with different diffusion times in one repetition time, both by utilizing a train of stimulated echoes. Each stimulated echo in the train of stimulated echoes is generated by a re- excitation radio-frequency (RE) pulse with a variable flip angle, following an initial 90 ° excitation RE pulse and a subsequent 90 ° restoration RE pulse.

IPC Classes  ?

• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

The present disclosure relates to compounds of formula I that can bind to one or more opioid receptors. In one aspect, the compounds described herein can bind to the kappa opioid receptor (KOR) and behave as an opioid receptor agonist. The ability of the compounds to bind to opioid receptors make them effective in the treatment or prevention of pain such as chronic pain.

IPC Classes  ?

• C07D 471/20 - Spiro-condensed systems
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

A system for fresh water generation may comprise an intake device positioned above an ocean or sea surface for capture of moisture-laden air. The system may comprise a condenser in fluid communication with the intake device for condensation of liquid water from the moisture-laden air captured by the intake device. The intake device may be disposed at or moveable to a vertical position above the ocean or sea surface where moisture flux of the moisture-laden air is at or above a predetermined value.

IPC Classes  ?

• E03B 3/28 - Methods or installations for obtaining or collecting drinking water or tap water from humid air
• A01G 9/14 - Greenhouses
• B01D 5/00 - Condensation of vapours; Recovering volatile solvents by condensation
• B01D 53/26 - Drying gases or vapours
• A01G 9/24 - Devices for heating, ventilating, regulating temperature, or watering, in greenhouses, forcing-frames, or the like

Abstract

Aspects of the subject disclosure may include, for example, a porous electrode that includes a porous layer, and a pattern of flow channels defined in the porous layer, wherein a first flow channel in the pattern of flow channels has a shape that at least partially approximates a cube-root profile. Additional embodiments are disclosed.

Abstract

Provided herein are methods of noninvasive detection of isotopically labeled essential amino acids, isotopically labeled metabolites of essential amino acids, or combinations thereof. In an aspect, a method can comprise feeding a subject a diet or supplement comprising isotopically labeled metabolites of essential amino acids such that the subject's tissue DNA methylation become isotopically labeled. The isotopically labeled DNA within a subject or a tissue can be detected with a magnetic resonance spectroscopy (MRS) scan or a magnetic resonance spectroscopic imaging (MRSI) scan.

IPC Classes  ?

• G01R 33/465 - NMR spectroscopy applied to biological material, e.g. in vitro testing
• G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy

Abstract

A listening system includes one or more remote signal sources that generate one or more electronic signals, which correspond to sound in an ambient environment. A first ear microphone detects a first combination of audio signals including ambient sound and one or more propagated audio signals, corresponding to the one or more electronic signals, received at a first ear of a listener. The system includes first ear playback device and a processing device to apply a first set of audio filters including an audio filter to process a respective electronic signal of the one or more electronic signals with a first error signal, which is based on an output of the first ear microphone, to generate a first output signal to the first ear playback device, wherein acoustic cue components of the first output signal match corresponding acoustic cue components of the first combination of audio signals.

IPC Classes  ?

• H04R 3/00 - Circuits for transducers
• H04R 25/00 - Deaf-aid sets

Abstract

A listening system includes a first microphone device and a second microphone device that generate a first electronic signal and a second electronic signal corresponding to sound within audio detection range. Control logic of the first microphone device detects a crosstalk audio signal from a direction of the second microphone device that matches the second electronic signal. The first electronic signal includes a mixture that includes the crosstalk audio signal. An ear playback device is associated with the second microphone device. A processing device receives the first electronic signal and the second electronic signal, removes the second electronic signal from the first electronic signal to generate a cleansed first electronic signal, and processes the cleansed first electronic signal to integrate the cleansed first electronic signal into an output signal to the ear playback device.

IPC Classes  ?

• H04M 9/08 - Two-way loud-speaking telephone systems with means for conditioning the signal, e.g.  for suppressing echoes for one or both directions of traffic
• H04R 25/00 - Deaf-aid sets
• H04R 3/00 - Circuits for transducers
• H04W 84/18 - Self-organising networks, e.g. ad hoc networks or sensor networks

Abstract

Herein is disclosed a bioinspired approach in which triggered conformational changes are used to control electron transfer (ET) events. Photo-induced conformational rearrangements of a ligand are translated into changes in the coordination geometry and environment about a bound metal ion. Taking advantage of the differential coordination properties of CuIand CuII, these dynamics facilitate intramolecular ET from CuIto the ligand to create a CS state. The synthesis and photophysical characterization of CuCl(dpaaR) (dpaa = dipicolylaminoacetophenone, with R = H and OMe) is presented. These ligands incorporate a fluorophore into their framework that gives rise to a twisted intramolecular charge transfer (TICT) excited state. Excited state ligand twisting provides a tetragonal coordination geometry capable of capturing CuIIorthoortho-OMe binding site is present (as in dpaaOMe).

IPC Classes  ?

• C07F 1/08 - Copper compounds
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A fusion protein composed of Notch1 or Notch4 EGF-like repeats 10-14 fused to human IgG Fc is described. Also provided is a pharmaceutical composition including the fusion protein and use of the fusion protein in methods of inhibiting angiogenesis and treating a disease or disorder.

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

22). Also disclosed are methods of using the pharmaceutical compositions for treating a disease or disorder (e.g., cystic fibrosis), increasing the pH of airway surface liquid, increasing bicarbonate secretion into airway surface liquid, and increasing a subject's forced expiratory volume in one second.

IPC Classes  ?

• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 47/02 - Inorganic compounds
• A61K 51/04 - Organic compounds
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Abstract

A microchannel includes a single inlet and a single outlet, a spiral section downstream from the single inlet, a straight section downstream from the spiral section, a detection section downstream from the straight section, and an expansion section downstream from the detection section and disposed between the detection section and the single outlet. The microchannel is to receive fluid having particles. In addition, at least the straight section and the detection section are configured to orient particles within the detection section in an area away from sidewalls of the detection section and into one of a single particle stream or two particle streams. The two particle streams immediately adjacent to each other appear as a single particle stream for optimized focusing and orientation of the particles in a focused stream within the microchannel.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• A61D 19/00 - Instruments or methods for reproduction or fertilisation
• A61K 35/52 - Sperm; Prostate; Seminal fluid; Leydig cells of testes
• G01N 15/14 - Electro-optical investigation

Abstract

This invention relates to ligand exchange proteins comprising the luminal domain of TAP-binding protein-related (TAPBPR), which functions as a MHC class I ligand-exchange catalyst when presented to mammalian cells either as a soluble extracellular protein or as a membrane bound cell surface protein. This may be useful in modulating immune responses, including for example loading immunogenic ligand onto tumors or other disease cells to induce their recognition by T cells. Ligand-exchange proteins and methods for their use are provided. The invention further relates to an approach for generating conditional peptide ligands for a range of disease-related MHC-I allotypes. The present invention relates to chicken and human TAPBPRs and tapasins as well as orthologs thereof, derivatives thereof, and any mutants thereof as well as any combinations thereof. The present invention also relates to placeholder conditional ligands for ligand-exchange reactions across multiple HLA allotypes.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The described technology induces sterility in female animals by a single injection of progestin containing implants formulated to elevate progesterone level for an extended period to neonatal animals. The sterilant can be progesterone or its derivatives which can activate progesterone receptors. Such formulation may be achieved by using a biodegradable copolymer that releases progesterone for more than 10 days. The progesterone-containing implant can be injected intramuscularly, subcutaneously, or intraperitoneally. The progesterone released from the implants over an extended period then prevents the development of uterine glands, thereby irreversibly sterilizing the female animals.

IPC Classes  ?

• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 15/18 - Feminine contraceptives

Abstract

Patches configured to hold an oncogenic cargo and deliver the cargo in a controlled manner to a predetermined location of a specified tissue are disclosed. As one example, a patch can comprise a base layer configured to adhere to a predetermined location of a tissue and a hydrogel layer. The hydrogel layer can comprise a plurality of microchannels that are configured to store and release a gene-modifying vector over a time period and in a quantity sufficient to produce a somatic cell tumor through manipulation of the genome of somatic cells at the predetermined location.

IPC Classes  ?

• A61F 13/02 - Adhesive plasters or dressings
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C07K 14/82 - Translation products from oncogenes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• C12N 5/09 - Tumour cells

Abstract

A system may include an object having a rotational axis. The system may also include a first mass movably mounted to the object and configured to adjust a moment of inertia of the object by translating relative to the object along an inertial path having a first component that is perpendicular to the rotational axis. The system may additionally include a second mass movably mounted to the object and configured to: apply to the object a first torque in a first direction along the rotational axis while the moment of inertia is adjusted above a threshold value and apply to the object a second torque in a second direction along the rotational axis while the moment of inertia is adjusted below the threshold value, by translating relative to the object along a torque path having a second component that is perpendicular to the rotational axis and the first component.

IPC Classes  ?

• B64G 1/24 - Guiding or controlling apparatus, e.g. for attitude control
• B64G 1/28 - Guiding or controlling apparatus, e.g. for attitude control using inertia or gyro effect
• B64G 1/38 - Guiding or controlling apparatus, e.g. for attitude control damping of oscillations, e.g. nutation dampers

Abstract

OO 6-methylguanine DNA methyltransferase (MGMT) while retaining suitable hydrolytic stability, allowing for effective prodrug activation and biodistribution. One compound, called TABZ, exhibits activity against cancer cells irrespective of MGMT expression and MMR status. TABZ has comparable blood-brain barrier penetrance and comparable hematological toxicity relative to TMZ, while also matching its maximum tolerated dose (MTD) in mice when dosed once-per-day over five days. The activity of TABZ is independent of the two principal mechanisms suppressing the effectiveness of TMZ, making it a promising new candidate for the treatment of GBM, especially those that are TMZ resistant.

IPC Classes  ?

• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/33 - Heterocyclic compounds
• C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
• C07D 487/04 - Ortho-condensed systems
• A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines

Abstract

A selected surface of the present disclosure is characterized by a two-tier nanostructure: first-tier nanostructures and second-tier nanostructures disposed on at least a cell wall of the first-tier nanostructures. The first-tier nanostructures define a network of cells, each with a cell wall and a recessed core. The core is predominantly formed of a first phase of an additively formed aluminum alloy, and the cell wall is predominantly formed of a second phase of the same additively formed aluminum alloy. A method of forming the two-tier nanostructure includes preferential etching of the core over the cell wall to form a network of open cells, and a self-limiting formation of the second-tier nanostructure to form a plurality of sub-cavities characterized by nanoscale dimensions smaller than the cell opening of a cell.

IPC Classes  ?

• B22F 10/20 - Direct sintering or melting
• C22C 21/02 - Alloys based on aluminium with silicon as the next major constituent
• C23F 1/20 - Acidic compositions for etching aluminium or alloys thereof
• F28F 13/04 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by preventing the formation of continuous films of condensate on heat-exchange surfaces, e.g. by promoting droplet formation
• F28F 13/18 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by surface treatment, e.g. polishing

Abstract

A radiological clip for locating marked tissue within a diagnostic ultrasound image may transmit an ultrasound identification (USID) signal within a bandwidth of ultrasound imaging pulses. A same ultrasound imaging array that receives the ultrasound imaging pulses may also receive the USID signal. An ultrasound imaging apparatus may generate an ultrasound image of the tissue that indicates a location and ID of the radiological clip based on the ultrasound imaging pulses and the USID signal received from the radiological clip within the imaging field. The radiological clip may generate an activation signal in response to receiving an ultrasound imaging pulse, generate an identification signal responsive to the activation signal, and transmit a USID signal based on the identification signal. The USID signal may include encoded signals corresponding to different bits within a multiple-bit identification tag to uniquely identify the radiological clip within a diagnostic image.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 90/90 - Identification means for patients or instruments, e.g. tags
• G01S 1/72 - Beacons or beacon systems transmitting signals having a characteristic or characteristics capable of being detected by non-directional receivers and defining directions, positions, or position lines fixed relatively to the beacon transmitters; Receivers co-operating therewith using ultrasonic, sonic, or infrasonic waves
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings

Abstract

A catalyst for hydrosilylation comprises a complex having a certain formula. The catalyst includes an imidazole moiety including at least one pendent substituent having a terminal ethylenic unsaturated group. A method of preparing the catalyst comprises reacting a platinum complex and an imidazole compound in the presence of a base reagent. A composition comprising the catalyst, an unsaturated compound (A), and optionally a silicon hydride compound (B) is further disclosed, along with a method of preparing a hydrosilylation reaction product.

IPC Classes  ?

• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 31/22 - Organic complexes

Abstract

A gas flow control device uses the curvature of nasal cannula or other tubes conveying the gas to control an actuator movable between two different configurations to permit or prevent gas flow. Curvature of the nasal cannula is measured by a sensor whose electrical resistance changes in response to the curvature of the sensor. The sensor is mounted on the cannula. Signals from the sensor are transmitted to a controller, which moves the actuator when the curvature exceeds or falls below a threshold value as measured by the change in electrical resistance of the sensor. The device finds use in oxygen therapy, where oxygen flow to a patient is cut off when the sensor indicates non-compliant behavior by the patient, indicating release of oxygen into the environment and causing a potential fire hazard.

IPC Classes  ?

• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
• A61M 16/08 - Bellows; Connecting tubes
• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

.. below ~65 °C, providing the ability for deposition on a wide variety of substrates including polymers and other flexible substrates.

IPC Classes  ?

• C23C 16/04 - Coating on selected surface areas, e.g. using masks
• H01L 21/30 - Treatment of semiconductor bodies using processes or apparatus not provided for in groups
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof

Abstract

The present disclosure relates to a plant or plant part comprising increased expression of a polynucleotide encoding a CYP72A219 polypeptide that confers to the plant or plant part tolerance to HPPD inhibitor herbicides, such as tembotrione or mesotrione. The disclosure further provides kits for identifying herbicide resistant plants and methods for determining whether a plant is herbicide resistant.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

Provided is a method of treating a disorder mediated by claudin-2 and/or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

222. Additional embodiments are disclosed.

IPC Classes  ?

• B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
• B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion

Abstract

Escherichia coliKlebsiella pneumoniaeEnterobacter cloacaeSalmonella typhimuriumSalmonella typhimurium, and is selective over Gram-negative and Gram-positive commensal bacteria, thereby avoiding perturbation of the gut microbiome.

IPC Classes  ?

• A61K 31/33 - Heterocyclic compounds
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

Aspects of the subject disclosure may include, for example, a porous device, comprising a porous material, and a hierarchical network of flow channels defined in the porous material, wherein at least one flow channel in the hierarchical network of flow channels has a shape that at least partially approximates a cube-root profile or a quartic-root profile. Additional embodiments are disclosed.

IPC Classes  ?

• C25B 11/031 - Porous electrodes
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms

Abstract

In accordance with the purpose(s) of the present disclosure, described herein are methods for treating cancer associated with a Ras mutation in a subject in need of treatment comprising administering to the subject an effective amount of a compound of formula I as described herein or a pharmaceutically acceptable salt thereof. The compounds described herein have improved efficacy compared to the benchmark BET inhibitor JQ-1 and comparable efficacy to high dose JQ-1 with respect to the treatment of PDAC. In one aspect, the compounds are administered in combination with an effective amount of an immune checkpoint inhibitor such as, for example, PD-1/PD-L1 inhibitor, a CTLA-4 inhibitor, or a combination thereof.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

According to one aspect of the disclosure, a method for measuring stress of a subject includes: transmitting, by a sensor, a wireless signal within an environment comprising the subject; measuring reflections of the wireless signal to generate a physiological signal responsive to changes in distance between the subject and the sensor over time; processing the physiological signal to extract feature data of the subject; and providing the feature data as input to a stress classification network to determine a stress level of the subject.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnics; Testing reaction times
• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

Abstract

22 support.

IPC Classes  ?

• C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
• C07C 43/04 - Saturated ethers
• B01J 21/00 - Catalysts comprising the elements, oxides or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium or hafnium

Abstract

Provided herein is an endovascular guide wire comprising an elongated proximal section; a distal tip; and one or more intermediate sections disposed between the proximal section and distal tip. The one or more intermediate sections includes a threedimensional spiral structure. The spiral structure can also be funnel-shaped. Also provided are systems include the endovascular guide wire and a catheter.

IPC Classes  ?

• A61M 25/09 - Guide wires
• A61M 25/00 - Catheters; Hollow probes
• A61M 25/04 - Holding devices, e.g. on the body in the body, e.g. expansible

Abstract

A process for producing an ether including treating (a) an ester with (b) hydrogen in the presence of (c) a heterogeneous catalyst to reduce the ester by hydrogenation to form an ether product, wherein the heterogeneous catalyst comprises a transition metal deposited on a zeolite support.

IPC Classes  ?

• C07C 41/01 - Preparation of ethers
• C07C 43/04 - Saturated ethers

Abstract

The technology disclosed herein provides (4aR,4bS,6aS,9aS,9bS)-1-(4-chlorobenzyl)-4a,6a-dimethyl-3,4,4a,6,6a,8,9,9a,9b,10-decahydro-1H-indeno[5,4-f]quinoline-2,5,7(4bH)-trione, identified as compound IB:10:D, and related compounds. Compound IB:10:D was discovered though screening a compound library for inhibitors of the enzyme SULT2B1b. This enzyme, which produces the product cholesterol sulfate, is overexpressed in cancer. The product acts as an immunosuppressant that results in suppression of the immune system's ability to clear tumor cells. Compounds related to IB:10:D were synthesized and shown to inhibit production of cholesterol sulfate. The discovered inhibitors of SULT2B1b provide new compounds and methods for immunotherapy and cancer treatment.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone

Abstract

The expression of the P-glycoprotein (P-gp) efflux transporter at the blood−brain interface impedes BBB penetrance of most small molecules. Designing efflux liabilities out of compounds can be laborious and there is no generalizable approach to transform periphery-limited agents to ones active in the CNS. A target-agnostic, prospective assessment of P-gp efflux using diverse compounds indicated a reduction in molecular size or appending a carboxylic acid that enabled evasion of P-gp efflux in cell-based experiments and in mice. Such strategy was applied to transform a periphery-limited V600EBRAF inhibitor, dabrafenib, into compounds that possess potent and selective anti-cancer activity, but now also evaded P-gp-mediated efflux. When compared to dabrafenib, the compound developed herein (everafenib) has superior BBB penetrance and superior efficacy in an intracranial mouse model of metastatic melanoma, suggesting it as a lead candidate for the treatment of melanoma metastases to the brain and gliomas with BRAF mutation.

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are compositions and methods for mechanochemical dynamic therapy.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

Recombinant polypeptides that include a chimeric secretory component (cSC) protein in which the D2 domain of secretory component is modified to confer one or more non-native properties to the polypeptide are described. The D2 domain can be modified, for example, to confer specific binding to a target molecule, such as by replacing the D2 domain with a single domain antibody or by modifying the D2 domain by replacement of complementarity determining region (CDR)-like loops with CDR sequences from a single domain antibody. The D2 domain can also be modified to enable fluorometric or colorimetric detection of the recombinant polypeptide. Methods of using the recombinant polypeptides, such as for treating or inhibiting a microbial infection, are also described. In some examples of these methods, the D2 domain of the recombinant polypeptide is modified to confer specific binding to a microbial antigen.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61K 39/40 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals

Abstract

Described here are systems and methods for super-resolution ultrasound microvessel imaging and velocimetry. The systems and methods utilize deep learning and parallel computing to realize real-time super-resolution microvascular imaging and quantitative analysis and display.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06T 7/00 - Image analysis
• G06T 7/20 - Analysis of motion

Abstract

in situ in situ curable hydrogel composition composed of decellularized corneal extracellular matrix functionalized with an acrylate in admixture with a photo-initiator, said hydrogel composition being of use in the treatment of an ocular surface wound.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cements; Adhesives for colostomy devices

Abstract

Herein disclosed is a new electrochemical approach to catalyst capture and recycling that overcomes conventional industrial recovery methods using functionalized redox-polymer electrodes. This technology provides a redox electro-separation system comprising polyvinylferrocene that was able to capture platinum group metal based catalysts directly from products and transfer to fresh reactants achieving 99.5% recovery without disturbing catalyst activity. Several reactions were tested along with various solvent-electrolyte matrices, showing >99% recovery efficiencies for platinum species as low as 1.6 ppm.

IPC Classes  ?

• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C25F 7/00 - Constructional parts, or assemblies thereof, of cells for electrolytic removal of material from objects; Servicing or operating

Abstract

A method of preparing a covalently conjugated composition includes contacting a MC-GAG scaffold with a solution containing l-ethyl-3-(3- dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS); and further contacting the scaffold with a solution that includes a cross-linking reagent, and a solution that includes OPG, an OPG fragment or an equivalent of each thereof.

IPC Classes  ?

• A61L 27/24 - Collagen
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules

Abstract

A plasma separation device including a blood inlet and a plasma outlet, the blood inlet comprising an inlet tunnel configured for loading a whole blood sample and a first chamber configured for collecting the whole blood sample; the plasma outlet comprising a second chamber for collecting plasma separated from the whole blood; the device comprising an anti-fouling membrane disposed between the blood inlet and the plasma outlet, the anti-fouling membrane comprising a zwitterionic polyurethane or pre-polymer thereof, wherein the zwitterionic polyurethane or pre-polymer thereof comprises a monomeric unit comprising a zwitterion or precursor thereof and optionally a monomeric unit derived from a polyol, wherein the monomeric unit derived from a polyol is present in a molar ratio in a range of about 0 to about 0.80 relative to the combined amount of monomeric unit derived from a polyol and the monomeric unit comprising a zwitterion or precursor thereof.

IPC Classes  ?

• B01D 65/08 - Prevention of membrane fouling or of concentration polarisation
• B01D 71/54 - Polyureas; Polyurethanes
• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• B01D 63/08 - Flat membrane modules

Abstract

An example embodiment may involve receiving, at a node of a radio access network, input signals on a plurality of wireless channels, wherein uplink channels in the plurality of wireless channels are respectively associated with downlink channels in the plurality of wireless channels; determining uplink characteristics for the uplink channels; providing, to a trained neural network, the uplink characteristics, wherein the trained neural network was iteratively trained, with a training data set of recorded uplink characteristics and recorded downlink characteristics, to form predictions of the recorded downlink characteristics from the recorded uplink characteristics, wherein the trained neural network includes an encoder that maps the recorded uplink characteristics to latent vector representations, and a decoder that maps the latent vector representations to the predictions; receiving, from the trained neural network, a prediction of downlink characteristics for the downlink channels; and transmitting, on the downlink channels, output signals based on the prediction.

IPC Classes  ?

• G06N 3/08 - Learning methods
• H04B 7/0413 - MIMO systems
• H04W 24/08 - Testing using real traffic
• G06N 20/00 - Machine learning
• H04L 5/14 - Two-way operation using the same type of signal, i.e. duplex

Abstract

Embodiments of the invention related generally to the treatment or prevention of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, more particularly, to the use of (S)-crizotinib or a pharmaceutically-acceptable salt thereof in such treatment or prevention. In one embodiment, the invention provides a method of treating a patient diagnosed with SARS-CoV-2, the method comprising: administering to the patient a dose of (S)-crizotinib or a pharmaceutically-acceptable salt thereof.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

In one aspect, the disclosure relates to a scaffold for a class of small molecules that selectively inhibit the α3β4 nicotinic acetylcholine receptor (nAChR) subtype, as well as molecules constructed using the scaffold and syntheses thereof. In some aspects, the scaffold can be used as a basis for synthesizing additional molecules capable of selectively inhibiting other nAChR subtypes. In a further aspect, the disclosed small molecules can be used as molecular probes to investigate the function of different nAChR subtypes and as potential treatments for addiction and other diseases.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 225/06 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• A61K 31/5545 -

Abstract

Immunogenic compositions that include a full-length influenza A virus matrix 2 (M2) protein, an amphipathic molecule, and at least one phospholipid, which assemble to form a nanodisc, are described. Use of the immunogenic compositions, for example as a universal influenza virus vaccine, is described.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C07K 14/775 - Apolipopeptides

Abstract

The present disclosure describes a nucleic acid-guided nuclease cascade assay that can detect one or more target nucleic acids of interest of interest at attamolar (aM) (or lower) limits in about 10 minutes or less without the need for amplifying the target nucleic acids of interest. The nucleic acid-guided nuclease cascade assays utilize signal amplification mechanisms comprising various components including nucleic acid-guided nucleases, guide RNAs (gRNAs), blocked nucleic acid molecules, blocked primer molecules, and reporter moieties.

IPC Classes  ?

• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6839 - Triple helix formation or other higher order conformations in hybridisation assays
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 9/14 - Hydrolases (3.)
• C12N 9/22 - Ribonucleases

Abstract

In some embodiments, a method of encoding a set of information bits to produce a codeword that encodes the set of information bits for reliable communication is provided. The set of information bits is received. The set of information bits are provided to a plurality of permutation layers separated by neural network processing layers. Each permutation layer accepts an input vector and generates a reordered output vector that is a reordering of the input vector. Each neural network processing layer accepts a vector of input values and generates a vector of output values based on a non-linear function of the vector of input values. The reordered output vector of a final permutation layer of the plurality of permutation layers is provided as the codeword. In some embodiments, a corresponding method of decoding a codeword to retrieve a set of information bits is provided.

IPC Classes  ?

• G06Q 50/18 - Legal services; Handling legal documents
• A63F 13/30 - Interconnection arrangements between game servers and game devices; Interconnection arrangements between game devices; Interconnection arrangements between game servers

Abstract

Provided herein are compositions and methods for suppressing mutant gene function using Cas13 nucleases that can be delivered to the spinal cord and brain to mediate the knockdown of genes that are causative for autosomal dominant neurodegenerative disorders.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• A61P 25/16 - Anti-Parkinson drugs

Abstract

A system for redox-mediated electrodialysis includes: a first electrode; a second electrode positioned in opposition to the first electrode; an anion exchange membrane and a cation exchange membrane positioned between the first and second electrodes; a feed channel for flow of a treating fluid, the feed channel extending between the anion and cation exchange membranes; an additional membrane or pair of membranes between the first and second electrodes, the additional membrane or pair of membranes defining a collection channel on one or both sides of the feed channel for collecting anions and cations removed from the treating fluid, the additional membrane or pair of membranes including an anion exchange membrane and/or a cation exchange membrane; and a redox channel for flow of a redox fluid, the redox channel containing the first and second electrodes and being separated from the feed and/or collection channels by the anion and/or cation exchange membranes.

IPC Classes  ?

• B01D 61/44 - Ion-selective electrodialysis
• B01D 61/46 - Apparatus therefor
• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor

Abstract

The disclosure provides a synthetic biology toolkit that enables precise and effective control of gene expression in A. tumefaciens and related Rhizobia. Inducible expression systems were constructed, characterized, and optimized to obtain an expression system regulated through amplifier introduction and promoter engineering, and cognate promoters were produced and evaluated. To establish a fine-tunability, a series of spacers and a promoter library were constructed to systematically modulate both translational and transcriptional rates. The application of the tools was demonstrated by coexpressing genes with altered expression levels using a single signal. The studies carried out provide precise expression tools, facilitating rational engineering of in A. tumefaciens and related Rhizobia bacteria for advanced plant biotechnological applications.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present disclosure provides technologies that allow reduced field of view or fast imaging with reduced image distortion. The first technique capitalizes on the benefit of reduced field of view imaging for full field of view coverage. The second technique allows achieves high resolution 3D images in a focused region. These techniques are expected to have applications for cancer imaging, neuro imaging, and other biomedical imaging areas.

IPC Classes  ?

• G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
• G01R 33/48 - NMR imaging systems
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography

Abstract

Redox copolymers for electrochemically-assisted electrosorption and release of an organic micropollutant from a contaminated water source are provided. Electrochemical systems including the redox copolymers immobilized to a first electrode such that the first electrode is configured to be tunable in redox activity, hydrophobicity, fluorophilicity, and/or binding affinity, and to be tunable toward a target molecule, are further provided. Methods of and systems for separating and degrading a target molecule in tandem from a fluid are further provided.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C25B 3/02 - Electrolytic production of organic compounds by oxidation
• G01N 27/30 - Electrodes, e.g. test electrodes; Half-cells

Abstract

DDD guide RNA molecules.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed herein are nanoparticles comprising Pazopanib or a derivative thereof encapsulated by the copolymer poly(lactic-co-gly colic acid) (PLGA). Also disclosed herein are methods for treating osteoarthritis, inhibiting or preventing cartilage degeneration, and reducing or inhibiting pain-associated depression in subjects with joint pain with nanoparticles comprising Pazopanib or a derivative thereof.

IPC Classes  ?

• A61K 31/33 - Heterocyclic compounds
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

This invention relates to a modified gasdermin protein having a photoactivatable linker inserted between the C- terminal domain and N-terminal domain a gasdermin protein, nucleic acids and vectors encoding the modified gasdermin protein, and methods of using the modified gasdermin protein to introduce agents into cells and facilitate the treatment of diseases or conditions.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Rare earth elements (REEs) play an essential role in our modern society, being critical resources for the growing electronic devices and renewable energy technologies. For the reversible capture and release of REEs, we designed and synthesized a redox-copolymer poly(ferrocenylpropyl methacrylamide-co-methacrylic acid) (P(FPMAm-co-MAA)) that combines an ion-exchange carboxylic acid group for REE adsorption, and an redox-active ferrocene moiety for electrochemical regeneration. By molecularly tuning the copolymer composition, efficient adsorption uptake could be achieved alongside electrochemically regenerated adsorbent reuse. The copolymer sorbent showed stoichiometric binding for yttrium (Y), cerium (Ce), neodymium (Nd), europium (Eu), gadolinium (Gd), and dysprosium (Dy) based on carboxylic acid active site.

IPC Classes  ?

• C09D 133/02 - Homopolymers or copolymers of acids; Metal or ammonium salts thereof
• C08L 33/02 - Homopolymers or copolymers of acids; Metal or ammonium salts thereof
• C08L 33/24 - Homopolymers or copolymers of amides or imides

Abstract

The disclosure provides example devices and methods for virus and bacterium detection and identification. The example device includes (a) a housing having an air inlet and an air outlet, (b) a substrate disposed within the housing, where the at least one substrate has a through-slot, where the substrate has a plurality of wells, (c) an air-handling and precipitation chamber, a reagent and reaction chamber, and a detection chamber arranged in series and each coupled to the top surface of the substrate, (d) a first actuator coupled to the substrate and configured to rotate the substrate, (e) a second actuator coupled to and configured to rotate the air-handling and precipitation chamber, the reagent and reaction chamber, and the detection chamber, and (f) at least one processor electrically coupled to the air-handling and precipitation chamber, the reagent and reaction chamber, the detection chamber, the first actuator, and the second actuator.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
• G01N 1/00 - Sampling; Preparing specimens for investigation
• G01N 15/06 - Investigating concentration of particle suspensions
• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor

Abstract

Aspects of the present disclosure relate to genetically altered plants with increased activity of one or more of a PPDK regulatory protein (PDRP), a Rubisco activase (Rea) protein, or a Rubisco protein that have increased photosynthetic efficiency under fluctuating light conditions. Further, aspects of the present disclosure relate to methods of producing and cultivating the genetically altered plants of the present disclosure.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A densely integrated and chiplet/dielet based networked memory pool with very high intra-pool bandwidth is provided. Chiplets are used to provide a common interface to the network. This means all memories (even those built with different process technologies) look the same from the network's perspective and vice versa; memory can be assembled in many different configurations while only changing the configuration at a high level of abstraction. The memory pool can easily be scaled in capacity and custom configurations that were previously impossible to achieve because of incompatibility of different technologies or level of integration are made possible.

IPC Classes  ?

• G06F 13/36 - Handling requests for interconnection or transfer for access to common bus or bus system
• G06F 13/00 - Interconnection of, or transfer of information or other signals between, memories, input/output devices or central processing units
• G06F 12/00 - Accessing, addressing or allocating within memory systems or architectures

Abstract

staacids and vectors encoding the fusion proteins, pharmaceutical compositions, immunogenic compositions, and vaccines. In examples, the methods include administering a disclosed composition to a subject, such as a human.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• C07K 14/28 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)

Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds and methods for activating NAMPT in a subject. The compounds described herein are useful in treating a neurological disorder, disease, or condition. In another aspect, compounds described herein are useful in treating metabolic disorders and diabetes. Formula (I)

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• C07D 487/04 - Ortho-condensed systems
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis.　The pharmaceutical composition of the present invention contains a monoclonal antibody molecule that fights against colicin, which is a peptide that stores a variety of staphylococcus strains including staphylococcus nepalensis, or a derivative of the monoclonal antibody molecule.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/085 - Staphylococcus
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/13 - Immunoglobulins
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12P 21/08 - Monoclonal antibodies
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Compounds that induce expression of ATP-binding cassette transporter Al (ABCA1 ) without lipogenesis are provided, as are methods of using the same to treat or prevent type 2 diabetes or dementia.

IPC Classes  ?

• C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/4436 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.

IPC Classes  ?

• G01N 33/531 - Production of immunochemical test materials
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/551 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
• G01N 33/553 - Metal or metal coated
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

E. coliK. pneumoniaeA. baumanniiA. baumannii. Fabimycin has activity in multiple mouse models of infection caused by Gram-negative bacteria, including a model of urinary tract infection. Fabimycin has translational promise, and its discovery provides data indicating that antibiotics whose spectrum of activity is restricted to Gram-positive bacteria can be systematically modified to accumulate in Gram-negative bacteria and be effective against these problematic pathogens.

IPC Classes  ?

• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• C07D 471/04 - Ortho-condensed systems
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 31/04 - Antibacterial agents

Abstract

Disclosed herein are methods and systems that use a photonic crystal (PC) for interference scattering microscopy. Incident light is directed onto a surface of the PC and couples into a photonic crystal guided resonance (PCGR) mode of the PC such that less than 1% of the incident light is transmitted through the PC as transmitted light. One or more particles adjacent to the surface of the PC scatter a portion of the light coupled into the PCGR mode as scattered light. An image comprising a pattern of constructive and destructive interference between the transmitted light and the scattered light is formed, and an image sensor may capture one or more image frames of the image. Imaging processing of the one or more image frames can be used to identify at least one scattering center corresponding to at least one particle of the one or more particles.

IPC Classes  ?

• G02B 1/02 - Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of crystals, e.g. rock-salt, semiconductors
• G02B 5/18 - Diffracting gratings
• G02B 5/20 - Filters
• G02B 6/14 - Mode converters

Abstract

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some aspects, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/00 - Antiparasitic agents

Abstract

Provided herein are PLpro inhibitors and methods of treating and/or preventing an infection caused by a coronavirus by administration of one or more of said PLpro inhibitors to a subject in need thereof, as well as pharmaceutical formulations and kits for use in these methods.

IPC Classes  ?

• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
• A61P 31/12 - Antivirals